Investor News

Tanai Therapeutics appoints Pieter Rottiers as Chief Executive Officer

  • A seasoned Chief Executive, with over 20 years of distinguished leadership in medical biotechnology ​
  • Poised to guide the Tanai team in advancing its groundbreaking, oral, first-in-class therapeutic targeting a genetically validated pathway for obesity treatment

Ghent, Belgium, 22 January 2025 – Tanai Therapeutics (“the Company” or “Tanai”), a VIB spin-off company developing a new therapeutic class of obesity treatments, today announces the appointment of Pieter Rottiers, as Chief Executive Officer (CEO) and Director.

Pieter Rottiers, PhD, has a proven track record of leading start-ups and emerging biotechnology companies to success, demonstrating exceptional expertise in advancing innovative solutions. As CEO of Precigen ActoBio Inc., he spearheaded early-stage and clinical programs targeting gastrointestinal and autoimmune disorders. His prior senior roles at Intrexon Actobiotics NV, ActoGeniX NV, and VIB further highlight his leadership in driving breakthroughs in molecular biology and biotechnology.

“On behalf of Tanai’s Board of Directors, I am delighted to welcome ​ Pieter Rottiers as the CEO of our Company,” said ​ Sara Vandenwijngaert, Chair of Tanai. “With his exceptional leadership in biotech and drug development, Pieter is perfectly poised to guide our mission of pioneering innovative, first-in-class therapies for obesity. We are confident his expertise will drive meaningful progress for the Company.”
“I am honored to take on this important role at Tanai”, added ​ Pieter Rottiers. “Tanai’s novel drug target holds immense potential in addressing obesity, a growing global challenge that is linked to numerous comorbidities. Backed by a strong investor syndicate and the deep scientific expertise of our team, Tanai is uniquely positioned to make transformative impact. I look forward to leveraging my experience and working alongside this talented team to drive the Company’s success.”

 

***ENDS***

 

Notes to Editors

 

Bio Pieter Rottiers, PhD

Dr. Pieter Rottiers is a seasoned executive with extensive expertise in medical biotechnology and drug development. He brings a wealth of experience from leadership roles in innovative biotechnology companies.

Prior to joining Tanai Therapeutics, Dr. Rottiers served as CEO and Director of Precigen ActoBio Inc. starting in 2018, where he successfully advanced a diversified portfolio targeting gastrointestinal and autoimmune disorders, including overseeing early-stage and clinical development programs. Under his leadership, the company made significant progress in advancing therapeutic candidates through various stages of clinical development. From 2015 to 2018, he was Vice President at Intrexon Actobiotics NV and served as Managing Director until 2024. Before that, he held senior roles at ActoGeniX NV, a VIB spin-off company acquired by Intrexon Corporation in 2015, and worked as Principal Investigator at the VIB-UGent Center for Inflammation Research.

Dr. Rottiers holds a PhD in Biotechnology from the University of Ghent and a postgraduate degree in Business Management from EHSAL Management School in Brussels.

 

About Tanai Therapeutics

Tanai Therapeutics is a Belgian biotech company pioneering a novel treatment for obesity. It was founded in 2023 as a spin-off from VIB and UGent with the support of V-Bio Ventures and Qbic. Its scientific foundation originates from the ground-breaking research of Prof. Savvas Savvides and Prof. Charlotte Scott from the VIB-UGent Center for Inflammation Research. Tanai Therapeutics is developing an oral, first-in-class therapeutic targeting a genetically validated pathway in obesity critical to energy expenditure. The company has raised over EUR 6 million in seed financing from a syndicate of investors, including V-Bio Ventures, Qbic, VIB, BioGeneration Ventures and Novo Nordisk.

 

For more information, please contact:

Tanai Therapeutics

Pieter Rottiers, CEO

E: Pieter.Rottiers@tanaitx.com

 

VIB Investor Relations

Lies Vanneste

E: IR@vib.be

M: +32 498 05 35 79

 

 

 

 

Share

Latest stories

Website preview
New tool makes gene regulation easier to study—and tweak
Leuven, 2 April 2026 - Understanding how genes are switched on and off in specific cell types remains one of biology’s central challenges. While AI has made major progress in decoding the regulatory logic of DNA, applying these approaches across datasets, tissues, and species has remained difficult. In a new Nature Methods paper, a research team led by Prof. Stein Aerts (VIB & KU Leuven) presents CREsted, a software package that enables both the analysis and design of gene regulatory elements in a systematic and scalable way.
press.vib.be
Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be